Our Top 5 Analyst Questions
Myriad Genetics reported flat year-over-year sales in Q2, but the market responded positively due to results that surpassed…
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
1 Attributable to UNH discontinuation of coverage (commercial and managed Medicaid) of GeneSight and the divestiture of the…